Duration of humoral immunity to common viral and vaccine antigens.
about
Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person SyndromeImmune mechanisms of protection: can adjuvants rise to the challenge?Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseasesRapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell culturesTranslating transitions - how to decipher peripheral human B cell developmentHITlights: a career perspective on heparin-induced thrombocytopeniaImmune regulation of human herpesviruses and its implications for human transplantationSerology in the 21st century: the molecular-level analysis of the serum antibody repertoireAnimal models of varicella zoster virus infectionVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseMelioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposesWanted, dead or alive: New viral vaccinesViral Vaccines and CTL ResponseYoung lives lost as B cells falter: what we are learning about antibody responses in malaria.Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and VaccinationPredicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobiumDengue: knowledge gaps, unmet needs, and research prioritiesInduction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in miceTetanus-diphtheria-acellular pertussis vaccination for adults: an updateNeutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.Prospects for developing an effective particle-mediated DNA vaccine against influenza.Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individualsRegulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.Mcl-1 is essential for the survival of plasma cells.Protective antiviral antibody responses in a mouse model of influenza virus infection require TACIImmunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialRecovery of an antiviral antibody response following attrition caused by unrelated infection.Influence of prior influenza vaccination on antibody and B-cell responses.Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies.A method for identification of HIV gp140 binding memory B cells in human blood.B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionLong-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivaxAdjuvant-specific regulation of long-term antibody responses by ZBTB20The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections
P2860
Q21136358-25BD166B-C07A-45D9-90CE-2E876DC0C5E0Q21245319-0219CE4A-B31B-45D6-8857-16ADF8FBB998Q24273331-9FF15F32-4CF3-4552-A838-9B30A83BAB57Q26700070-B336AD48-E189-4A79-9316-1DC0CD7D76ADQ26799037-D5A38994-7D1D-4458-9078-F6FBFAA6FA27Q26828351-46E435E1-37EC-4B14-B147-DB0778121941Q26992146-E182DD36-0D45-4588-986A-FCBD68076497Q26997997-50F545CE-DDD9-46DB-A650-BD9E8D617EADQ27011703-85EBE93E-473D-4F68-896E-99991CBF8852Q27014663-3D5AAF60-2F48-4A81-ACD2-068A67BD1CC0Q27305733-BC4C72DC-FEB8-4994-8BCA-8137481E6452Q27489979-2E40A441-F3C9-431E-B1AF-22190B38C4C0Q27491330-40219F15-C0D7-4BF1-9C0C-EA5D88BC5EB5Q27687235-0D6FC49E-3B9F-4830-8F39-B31D0407D9DAQ28114614-F34C0557-7C28-4D2C-B55B-F303980D166BQ28541406-9AD29DF6-17EF-42F1-9CD8-A8DE7F6722F3Q28729764-D571AF79-4AB5-4E3E-B9B5-08FA46F00046Q28741242-7665F051-D765-4A9B-8693-32A54EB420F3Q28752489-92E74C3F-1DDE-4911-82E6-9D69AD71B33DQ30238516-D0760BCC-44EA-4AD9-9D59-4FF44876EDEDQ30352862-88830104-BCCE-4B1C-A78D-9CAB1B6530E8Q30371297-340BB51F-4E0F-4815-A5C5-63E2B8602F2AQ30371529-1CA7ED21-1224-46CB-A17D-773BBD2E74B2Q30380300-AFFBE620-AD73-4471-AB42-9A68F970336CQ30397400-ACB06366-29BF-44FE-BC31-D57E92793D16Q30400347-C41C99C6-CD2D-4E28-9969-C7C3BD4AA6CCQ30412266-4CC1C319-A013-44C1-813C-CEFB3C052BF0Q30412677-CB34C611-3FFF-4644-853E-60C53BBDE097Q30430255-3273F687-B138-4114-BCE8-AF1AC3971E41Q30991737-60E291EF-C156-4622-87F5-CCEBD9B9C7A0Q31147149-6C39D82B-2F7D-4DFB-AFD0-2D4B99E407D9Q33361605-7D4DAF0A-A376-42A6-BF67-B49064746662Q33384840-7DDD565F-530D-488C-AD62-84C9B6DF4800Q33394829-B2A4E7F6-BAB3-4BA6-BD42-165BC581390BQ33404838-8DA1CD84-9041-418E-8B74-556C000C0E00Q33410222-3D824A08-60C0-4E88-B515-FAE4DC82E11DQ33479167-31DE48BC-9A35-4EF5-A985-41E798FAD84EQ33533328-5B9CBFE6-858F-4CFD-96A6-BB017B1BCFF9Q33569857-768008E3-E28E-4320-BA21-238DE0FA6441Q33587496-2ACFE61F-65EC-450F-A9C4-081F8F192B86
P2860
Duration of humoral immunity to common viral and vaccine antigens.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Duration of humoral immunity to common viral and vaccine antigens.
@en
Duration of humoral immunity to common viral and vaccine antigens.
@nl
type
label
Duration of humoral immunity to common viral and vaccine antigens.
@en
Duration of humoral immunity to common viral and vaccine antigens.
@nl
prefLabel
Duration of humoral immunity to common viral and vaccine antigens.
@en
Duration of humoral immunity to common viral and vaccine antigens.
@nl
P2093
P356
P1476
Duration of humoral immunity to common viral and vaccine antigens.
@en
P2093
Ian J Amanna
Mark K Slifka
Nichole E Carlson
P304
P356
10.1056/NEJMOA066092
P407
P577
2007-11-01T00:00:00Z